Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · Real-Time Price · USD
4.260
-0.320 (-6.99%)
Mar 31, 2025, 4:00 PM EDT - Market closed
Protara Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Protara Therapeutics stock have an average target of 22.67, with a low estimate of 20 and a high estimate of 25. The average target predicts an increase of 432.16% from the current stock price of 4.26.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Protara Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 2 | 2 | 2 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 | 2 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 2 | 2 | 3 | 3 | 3 | 4 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Mar 14, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +439.91% | Mar 6, 2025 |
Guggenheim | Guggenheim | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +369.48% | Dec 6, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +439.91% | Dec 6, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +439.91% | Nov 14, 2024 |
Financial Forecast
Revenue This Year
n/a
from 217.20M
Revenue Next Year
n/a
EPS This Year
-1.78
from -2.17
EPS Next Year
-2.14
from -1.78
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | n/a | 161.5M | ||
Avg | n/a | n/a | 56.6M | ||
Low | n/a | n/a | 5.6M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -1.16 | -1.52 | -1.67 | ||
Avg | -1.78 | -2.14 | -2.05 | ||
Low | -2.21 | -2.69 | -2.70 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.